V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 15.4 DKK -6.67% Market Closed
Market Cap: 119.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ViroGates A/S
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Cash from Operating Activities
-kr12m
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Cash from Operating Activities
kr3.2B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
10%
Ambu A/S
CSE:AMBU B
Cash from Operating Activities
kr813m
CAGR 3-Years
35%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Cash from Operating Activities
kr3.6B
CAGR 3-Years
2%
CAGR 5-Years
16%
CAGR 10-Years
11%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
119.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.42 DKK
Overvaluation 78%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Cash from Operating Activities?
Cash from Operating Activities
-12m DKK

Based on the financial report for Sep 30, 2024, ViroGates A/S's Cash from Operating Activities amounts to -12m DKK.

What is ViroGates A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
20%

Over the last year, the Cash from Operating Activities growth was -20%. The average annual Cash from Operating Activities growth rates for ViroGates A/S have been 20% over the past three years .

Back to Top